Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway - Scorecard - MDSpire

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • By

  • Biao Zheng

  • Guojun Yao

  • Yuli Pang

  • Jielong Luo

  • Zhiyong Yang

  • Fengmin Xiu

  • Chaohui Zhen

  • Rui Liang

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: Tetrandrine Boosts the Effectiveness of Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma via Activation of the STING/TBK1/IRF3 Signaling Pathway

At a Glance

CategoryDetail
Condition
Key MechanismsActivation of STING/TBK1/IRF3 signaling pathway (ensure direct attribution).
Target Population
Care Setting

Key Highlights

  • Tetrandrine (TET) enhances CD8+ T cell activation and cytotoxicity against cancer cells (ensure direct attribution).
  • TET increases cytoplasmic dsDNA accumulation (ensure direct attribution).
  • TET activates STING/TBK1/IRF3 signaling pathway (ensure direct attribution).

Guideline-Based Recommendations

Diagnosis

    Management

    • C
    • o
    • m
    • b
    • i
    • n
    • a
    • t
    • i
    • o
    • n
    • o
    • f
    • T
    • E
    • T
    • w
    • i
    • t
    • h
    • a
    • n
    • t
    • i
    • -
    • P
    • D
    • -
    • 1
    • i
    • m
    • m
    • u
    • n
    • o
    • t
    • h
    • e
    • r
    • a
    • p
    • y
    • i
    • s
    • s
    • u
    • g
    • g
    • e
    • s
    • t
    • e
    • d
    • f
    • o
    • r
    • e
    • n
    • h
    • a
    • n
    • c
    • e
    • d
    • a
    • n
    • t
    • i
    • -
    • t
    • u
    • m
    • o
    • r
    • e
    • f
    • f
    • e
    • c
    • t
    • s
    • (
    • e
    • n
    • s
    • u
    • r
    • e
    • d
    • i
    • r
    • e
    • c
    • t
    • a
    • t
    • t
    • r
    • i
    • b
    • u
    • t
    • i
    • o
    • n
    • )
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients diagnosed with hepatocellular carcinoma, particularly those not suitable for radical surgery.

        TET may enhance the effectiveness of existing immunotherapies by promoting immune cell infiltration.

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

          • by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

          • June 9, 2026

          Related Content

          Editorial: Artificial intelligence advancing lung cancer screening and treatment

          Splenic flexure colon cancer may represent a distinct prognostic subtype associated with elevated systemic inflammation and impaired nutritional status

          Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review